Retatrutide

If you’re here, you probably saw the headline weight-loss number, found retatrutide for sale by the vial one search later, and want to know whether those two things are the same thing.

Retatrutide is the “triple agonist,” an investigational once-weekly shot that drove an average 28.3% body-weight loss at its top dose in phase 3 trials, the biggest numbers any GLP-1-class drug has posted. The catches are honest ones: it isn’t FDA-approved (2026), and every vial sold online is unregulated research material, not Lilly’s trial medicine.

What people actually use retatrutide for — and what they report

On the research-peptide forums, retatrutide gets run for one thing above all: aggressive fat loss. Not “drop a few pounds” — people arrive after watching the trial numbers and deciding they want the strongest lever in the class. The online crowd tends to skew younger and leaner than the trial population, whose entry point was clinical obesity; a lot of retatrutide’s following is people cutting for a physique, not treating a disease. That’s who’s actually holding the syringe, stated plainly.

What they report — the wins. The first thing people describe isn’t the scale, it’s the quiet. “Food noise,” the constant background negotiation with the fridge, tends to go silent within three to five days of the first shot, and that’s the effect users say they’d come back for even if the weight moved slower. Visible loss usually shows by week two or three. Self-reported totals people post cluster around 15% of body weight by six months and 18–22% by a year: real, but a few points under the trial figures, which fits home dosing, loose adherence, and gray-market vials of uncertain strength. One retatrutide-specific quirk comes up constantly: people run hot. A mild internal heat, more sweating, a flushed feeling in the hours after the shot. The community pins it on the glucagon arm turning up energy expenditure, and it lines up with what trial participants described.

What they report — the letdowns. The honest mix includes plenty that isn’t glowing. Nausea during titration is close to universal, constipation shows up more than diarrhea, fatigue lands hard in the first weeks of each new dose, and sulfur burps, heartburn, and some hair shedding around month three are common enough to be running jokes in the weekly threads. Plateaus frustrate people, and the seasoned advice is to hold a dose six-plus weeks and fix protein and training before chasing a bigger number. The muscle-loss worry is real and sorts cleanly by behavior: people who lift keep more than people who only diet or do cardio. And there are flat non-responders and quitters. Even the trials had people drop out over side effects, so “everyone melts” is survivorship talking, not the whole room.

The doses people actually run (anecdotal — not a validated protocol): almost everyone starts well below the 12 mg trial ceiling and climbs slowly to keep nausea livable. A common ladder is 0.5–2 mg weekly to start, bumped every four weeks (roughly 1 → 2 → 4 → 6 → 9 → 12 mg), taking three to four months to reach the top. A big share of people simply park at 6–8 mg indefinitely, deciding the extra loss at 12 mg isn’t worth the extra misery. Evening injection is the folk fix for nausea. None of these are clinical instructions; they’re peer conventions, and they carry exactly the reliability that implies.

The part the forums say a little quieter: there is no legal consumer version of this. Everything for sale is labeled “research use only” or “not for human consumption” and used by people anyway, most of it traced back to overseas synthesis labs, and the FDA has publicly warned against exactly these “research-only” versions being sold for human use (FDA). You end up as your own prescriber, pharmacist, and monitoring nurse — an arrangement that works right until it doesn’t.

What is retatrutide?

Retatrutide (development code LY3437943) is a synthetic peptide built by Eli Lilly that switches on three metabolic receptors at once: GIP, GLP-1, and glucagon. That’s why people call it the “triple agonist” or “triple-G.” The first two are the same receptors behind semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro); the glucagon receptor is retatrutide’s addition. It’s a once-weekly injection under the skin with a ~6-day half-life, which is what makes weekly dosing possible (phase 1b pharmacokinetics trial). It’s not a supplement and not an approved medicine. As of 2026 it’s an investigational drug still working through trials, and it lives in the GLP-1 and metabolic peptides hub with the rest of the incretin family.

How does retatrutide work?

Retatrutide imitates three of your own gut-and-metabolism hormones with a single molecule. Picture three switches wired to one button. The GLP-1 and GIP switches slow the stomach, quiet appetite, and sharpen the insulin response to a meal — the “I’m full, blood sugar handled” signal the current weight-loss drugs already lean on. The glucagon switch is the twist. Glucagon nudges the body to spend more energy and burn fat in the liver, a small metabolic furnace running alongside the appetite brake. Pairing an appetite brake with an energy-expenditure bump is the mechanistic reason researchers expected retatrutide to push weight further than a GLP-1 drug alone (phase 2 obesity trial, NCT04881760), and it’s the likely source of the “running hot” the community keeps describing.

Does retatrutide actually work? What the science says

Here’s what makes retatrutide unusual on this site: the answer is a real, human-trial yes. Most compounds we cover lean on animal data. Retatrutide has phase 3 randomized-controlled-trial evidence for its headline use. In TRIUMPH-1, adults with obesity or overweight on 12 mg weekly lost an average of 28.3% of body weight at 80 weeks; a prespecified extension in people who started at BMI 35 or higher reached 30.3% at 104 weeks, surgery-adjacent numbers from a weekly shot (TRIUMPH-1 results).

The rest of the program keeps pointing the same way. TRIUMPH-4 (445 adults with obesity and knee osteoarthritis, 68 weeks) posted 28.7% mean weight loss at 12 mg and cut WOMAC knee-pain scores more than placebo (TRIUMPH-4 results; NCT05931367). A TRIUMPH-1 basket trial in obstructive sleep apnea dropped the apnea-hypopnea index by up to 36.1 events per hour (60.6%) at 80 weeks (Lilly, June 2026). In type 2 diabetes, TRANSCEND-T2D-1 lowered A1c by 1.7% to 2.0% across doses with 16.8% weight loss at 12 mg by 40 weeks (TRANSCEND-T2D-1 results).

The peer-reviewed floor under those company-reported phase 3 numbers is the published phase 2 work: 338 adults, average weight change 24.2% down at 12 mg versus 2.1% down on placebo at 48 weeks (phase 2 RCT, PMID 37366315), plus a 98-person substudy where liver fat fell roughly 81–82% at the higher doses (phase 2a liver-fat RCT, PMID 38858523).

So the honest read is different from most pages here. The efficacy question isn’t the gap; phase 3 answered it. What’s still open is narrower and specific: retatrutide isn’t approved yet, the long-term heart-and-kidney outcomes trial (TRIUMPH-Outcomes, NCT06383390) hasn’t reported, and the head-to-head against tirzepatide is still running. Lilly has said it plans 2026 regulatory submissions for obesity, sleep apnea, and knee-osteoarthritis pain (Lilly Q4 2025 presentation). In other words, the next milestones for retatrutide aren’t “will it work,” they’re “when does it get approved” and “how does it hold up tested directly.”

Question	Best human evidence available	What it establishes	What remains open
Weight loss	Phase 3 TRIUMPH-1, 80 weeks	28.3% average loss with 12 mg versus 2.2% with placebo	Full peer-reviewed phase 3 publication and longer follow-up
Type 2 diabetes	Phase 3 TRANSCEND-T2D-1, 40 weeks	A1c fell 1.7% to 2.0% across retatrutide doses	More TRANSCEND results and direct comparisons
Liver fat	Phase 2a substudy, 98 participants	Liver fat fell sharply at 8 mg and 12 mg	Dedicated liver-disease outcomes beyond imaging
Knee osteoarthritis pain	Phase 3 TRIUMPH-4, 445 participants, 68 weeks	WOMAC pain improved with 9 mg and 12 mg versus placebo	Full peer-reviewed report, durability, and regulatory review
Obstructive sleep apnea	Phase 3 TRIUMPH-1 basket trial, 80 weeks	Apnea-hypopnea events fell from baseline	Full peer-reviewed report and regulatory review
Heart and kidney events	Ongoing TRIUMPH-Outcomes trial	The question is being tested in people	Heart attacks, strokes, kidney decline, and mortality results

Is retatrutide safe? Side effects

Retatrutide’s safety picture is better documented than most peptides here, and still incomplete. The dominant effects in trials are gastrointestinal — nausea, vomiting, diarrhea, and constipation — dose-related and worst while the dose is climbing, easing as the body adjusts. In TRIUMPH-1, nausea ran 28.6%, 38.4%, and 42.4% at 4, 9, and 12 mg versus 14.8% on placebo (Lilly phase 3 results). Retatrutide also raises heart rate in a dose-dependent way, and the long-term meaning of that is still being studied (phase 2 trial, NCT04881760).

Phase 3 added dysesthesia, an altered or tingling skin sensation, at 8.8% (9 mg) and 20.9% (12 mg) versus 0.7% on placebo in TRIUMPH-4, described as generally mild and rarely a reason people stopped (TRIUMPH-4 results). Rarer but serious events in the phase 2 obesity dataset included one acute pancreatitis and one cholecystitis case; small numbers can’t pin down a precise long-term rate (phase 2 obesity RCT).

The most-discussed serious concern is a class one. GLP-1-family drugs caused thyroid C-cell tumors in rodents, which is why the whole class carries a caution for anyone with a personal or family history of medullary thyroid cancer or MEN 2 syndrome. That signal is rodent-level and its human relevance is unsettled: a reason for caution and monitoring, not an established human harm.

Then there’s the risk that has nothing to do with the molecule. Gray-market retatrutide isn’t tested for purity, sterility, or dose accuracy, and there is now a real-world example of that going wrong, covered in the sourcing section below.

FDA & legal status (2026)

Retatrutide is not FDA-approved for any use as of July 2026. It’s an investigational drug in Eli Lilly’s pipeline, not a dietary supplement, and FDA’s position goes past “not yet approved”: retatrutide cannot lawfully be used in compounding under federal law, and the agency warns against versions falsely labeled “for research” while being sold for human use (FDA’s 2026 GLP-1 warning).

Registered clinical trials are the only legitimate way to receive retatrutide itself today. An online “research” sale is not an FDA-reviewed pharmacy product, whatever words like “pharmaceutical,” “clinical,” or “compounded” appear on the site. The phase 3 program is moving fast and Lilly has signaled 2026 submissions, so treat this as a dated snapshot, not a permanent state.

For athletes: WADA doesn’t name retatrutide, but because it isn’t approved for human use anywhere, it falls under the S0 (non-approved substances) category and is prohibited at all times under the 2026 anti-doping rules.

How is retatrutide dosed, reconstituted, and stored?

In the clinical trials, retatrutide was a once-weekly subcutaneous injection, started low and titrated up over weeks to blunt nausea, with the phase 2 obesity study testing up to 12 mg weekly and the largest weight loss at the top dose (NCT04881760). Those are doses reported in cited studies, not a personal protocol — this page informs, it doesn’t prescribe.

There is no publicly validated answer to “how long does reconstituted retatrutide last?” for gray-market vials. The public phase 2 protocol describes trial-site staff preparing a vial-and-syringe product under monitored storage, but it doesn’t publish a diluent, concentration, or beyond-use date you can transfer to an online powder (phase 2 protocol). So the common “28-day” rule floating around isn’t retatrutide data, it’s a generic guess wearing a lab coat. Our reconstitution and dosing calculator will check the concentration arithmetic, but arithmetic can’t establish chemical stability or sterility, and the mixing compatibility reference logs same-syringe compatibility for retatrutide as undocumented rather than pretending a blank file is a green light.

Where people get retatrutide — and what to check

There’s no FDA-approved retatrutide prescription and no lawful compounded version, so a “retatrutide for sale” result is always offering unapproved research material, not a pharmacy copy of Lilly’s trial drug. The same peptide name does not mean the same finished medicine. Lilly controls the active ingredient, formulation, storage, and accountability inside its trials; an online vial arrives outside all of that, and a posted certificate doesn’t turn its contents into an FDA-reviewed drug.

This isn’t hypothetical. In June 2026, Victoria’s Department of Health reported six cases of acute liver injury in people who used unapproved products labelled Retatrutide, Reta, R-10, or R-20, with investigators suspecting contaminants and still testing the products (Victoria health alert). That doesn’t implicate Lilly’s trial drug. It’s the contrast that matters: sponsor-controlled retatrutide reduced liver fat in the trials, while products merely wearing its name were linked to liver injury.

Route	What it is	Oversight	US human-use status
Registered trial	Sponsor-controlled investigational medicine	Protocol, monitored storage, site accountability	Legitimate for enrolled participants
Online “research” vial	Seller-supplied chemical, usually lyophilized	Vendor plus any hired lab; no FDA premarket review	Not approved or lawfully compounded
Approved incretin Rx	FDA-approved semaglutide or tirzepatide	Reviewed manufacturing, labeling, pharmacy chain	By prescription, for approved uses

A certificate of analysis narrows uncertainty only for the sample and tests it actually covers. FDA guidance says a real one identifies the batch, names the original manufacturer, lists each test and its limit, gives numerical results, and is signed and dated by quality staff (FDA Q7A guidance); if the batch number doesn’t match your vial, it isn’t evidence about your vial. And purity is a different question from sterility. FDA treats sterility and bacterial endotoxin as separate tests for injectables (FDA Q6A guidance), so a clean purity chromatogram says nothing about whether the vial is sterile. A COA is a receipt from a lab, not a force field.

Retatrutide vs tirzepatide and semaglutide

The whole class comes down to how many receptors each drug hits. Semaglutide hits one (GLP-1). Tirzepatide hits two (GIP + GLP-1) and is FDA-approved. Retatrutide hits three by adding glucagon, and is still investigational. That extra glucagon arm, the energy-expenditure furnace, is the reason its weight-loss numbers run highest and the reason users report running warm.

On paper, retatrutide’s top-dose loss (28.3% at 80 weeks) sits above the figures tirzepatide and semaglutide posted in their own trials, but those are separate studies, not a head-to-head, so the edge is suggestive, not settled. A direct retatrutide-versus-tirzepatide trial (TRIUMPH-5, NCT06662383) is running to answer exactly that. The full side-by-side is on the retatrutide vs tirzepatide comparison; it’s worth reading next to tirzepatide and semaglutide themselves, and survodutide, a GLP-1/glucagon dual, is the useful sibling for isolating what retatrutide’s glucagon arm actually adds.

Frequently asked questions

Does retatrutide actually work for weight loss?

Yes, in the strict human-trial sense, more than almost any peptide we cover. A phase 3 trial reported 28.3% average body-weight loss at 80 weeks on 12 mg versus 2.2% on placebo, with a BMI-35-and-up extension reaching 30.3% (TRIUMPH-1 results). Other phase 3 obesity trials are still running.

How is retatrutide different from tirzepatide and semaglutide?

Semaglutide hits one receptor (GLP-1), tirzepatide two (GIP + GLP-1), and retatrutide three by adding glucagon. The glucagon arm is thought to raise energy expenditure, which is why retatrutide’s numbers run highest and why users report feeling warmer than they did on other GLP-1 drugs.

What are retatrutide’s side effects?

Mostly gastrointestinal — nausea, vomiting, diarrhea, constipation — dose-related and heaviest while titrating up. It also raises heart rate, can cause tingling skin sensations at higher doses, and shares the incretin class’s rodent thyroid C-cell caution, whose human relevance is still unsettled.

Can you buy retatrutide legally?

Research material is advertised online, but it isn’t an FDA-approved medicine or a lawful compounded prescription. FDA says retatrutide can’t be used in compounding and warns against “research-only” versions sold for human use; legitimate access is through registered trials as of July 2026.

How long does reconstituted retatrutide last?

There’s no publicly validated retatrutide-specific beyond-use date for the powder sold online. The public phase 2 protocol doesn’t supply a shelf-life number that transfers to gray-market vials, so common 28-day claims aren’t established retatrutide data.

Is retatrutide banned in sport?

Effectively yes. WADA doesn’t name it, but because it isn’t approved for human use anywhere, it falls under the S0 “non-approved substances” category and is prohibited at all times for tested athletes.

Who is retatrutide for — and who should be cautious?

Retatrutide pulls in two crowds: people who’ve fought their weight for years, and people chasing a lean physique who watched the trial numbers and want the strongest lever in the class before it reaches pharmacies. What’s solid is the part most compounds here can’t claim — the efficacy is real and human-tested, with pivotal phase 3 results reported and more on the way. This isn’t a hopeful animal story; it’s a drug the data already backs for weight loss.

What’s still uncertain is the part that should slow a person down. Retatrutide isn’t approved yet, the long-term heart-rate and thyroid questions are still being filled in, and a gray-market vial isn’t reviewed for purity, sterility, or dose. Anyone with a personal or family history of medullary thyroid cancer or MEN 2, anyone pregnant or breastfeeding, and anyone unwilling to be their own unmonitored prescriber has real reason to wait for the approved product.

So, back to that headline number and the checkout page one click away. The number is real; retatrutide earned it in phase 3, which is more than almost anything else on this site can say. The gap isn’t whether it works. It’s the distance between Lilly’s monitored trial drug and an unlabeled powder from an overseas lab, and that gap is closing on a visible schedule: 2026 submissions, a head-to-head readout, an outcomes trial. Watching it close is a lot safer than standing in it.